Besides a spec FOMO run up ...will depend on the update of the open label trial ....the more they report on the lower the chance of a placebo effect ...and the 2nd Interim DMC report .
If the DMC decides to stop the trial for overwhelming efficacy ....and it would have to be really overwhelming efficacy ....then this should easily trade over $1